Cantargia obtains patent approval in China for therapy against IL1RAP in acute lymphoblastic leukemia

The Chinese patent office, State Intellectual Property Office (“SIPO”) has granted formal patent approval for Cantargia AB’s (“Cantargia”) application for use of IL1RAP as target molecule for antibody-based therapy of acute lymphoblastic leukemia (“ALL”).

The approved patent with number ZL201080047833.3 provides protection until 2030 and covers Cantargia’s method of using IL1RAP as target molecule for treatment of ALL. Cantargia has previously received patent approvals for IL1RAP as target molecule for antibody-based therapy for various forms of leukemia in Europe, the United States, Japan, South Africa, Mexico and Australia.

“China is a growing market that is very important for Cantargia”, Göran Forsberg, CEO of Cantargia AB, says. “The granting of our first patent in China is therefore of high importance for Cantargia”.

For further information, please contact 

Göran Forsberg, CEO 
Telephone: +46 (0)46-275 62 60
E-mail: goran.forsberg@cantargia.com

This constitutes information that Cantargia is required to publish under the EU’s Market Abuse Regulation. The information was submitted for publication through the above contact person on 1 June 2017, at 13:45.

About Cantargia 

Cantargia AB (publ), reg.no. 556791-6019, is a biotech company that is developing an antibody-based cancer treatment, which aims to attack cancer cells and arrest the inflammation of the tumour. The original discovery by the research team behind Cantargia was the overexpression of a specific target molecule, interleukin 1 receptor accessory protein “IL1RAP”, in cancer stem cells in patients with leukemia that is not found in normal stem cells in the bone marrow. In preclinical studies (in vitro and in vivo) the antibody, targeted at IL1RAP, has been shown to have two potential mechanisms of action, which are complementary. The Company has selected a product candidate, CAN04, for future studies in humans and development activities have been focused on non-small cell lung cancer and pancreatic cancer.

Cantargia is listed on Nasdaq Stockholm First North (ticker: CANTA). Sedermera Fondkommission is the company’s Certified Adviser. More information about Cantargia is available at http://www.cantargia.com.